4SCAR19 and 4SCAR22

Preclinical

SShenzhen Geno-Immune Medical Institute

4SCAR19 and 4SCAR22 is one of 19 therapeutic programs targeting B-cell Malignancies. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

B-Cell MalignanciesRecruiting

B-Cell MalignanciesPreclinical

Recruiting

Competition

Competitive Landscape

26 competitors in B-Cell Malignancies

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Phase 3

2 2

Brukinsa

BBeOne Medicines

Phase 3

5 3

Fludara

Sanofi

Phase 2

8 4

Cytoxan

BBaxter Healthcare Corporation

Phase 2

8 5

Libtayo

Regeneron

Phase 1

1 6

Treanda

AAzurity Pharmaceuticals

Phase 1

1 7

Fabhalta

BBellicum Pharmaceuticals

Phase 1

1 8

Odronextamab

Regeneron

Phase 1

2 9

Parsaclisib

Incyte

Phase 2

2 10

IL-2

FFate Therapeutics

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

B-cell Malignancies1 trial

Combination CAR-T Therapy of 4SCAR19 Plus 4SCAR20, 22, 38, 70 and 123 Targeting Hematological Malignancies

Terminated·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT03125577·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 4SCAR19 and 4SCAR22. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 4SCAR19 and 4SCAR22. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Shenzhen Geno-Immune Medical Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: SShenzhen Geno-Immune Medical Institute

4SCAR19 and 4SCAR22

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

B-cell Malignancies1 trial

References

Drug Info

Quick Facts

Related News